Background: The potential role of decreased respiratory muscle mass, if any, in mediating the susceptibility to exacerbation in COPD patients has not been determined. We hypothesized that a decrease in respiratory muscle mass is associated with increased risk of multiple hospital admissions due to acute exacerbations of the disease. Methods: Eligible cases and controls (n Z 20) were identified from records of our department's pulmonary clinic. Ten subjects diagnosed with COPD (males, 66 AE 7 yr, Body Mass Index (BMI) Z 26 AE 4 kg/m 2 ) were identified as fragile patients. Fragility was defined as four or more admissions in the previous year due to severe exacerbations of the disease. Fragile patients were matched with 10 non-fragile controls, defined as COPD patients who had required only one admission due to exacerbation of the disease. Criteria for 1:1 matching included ethnicity, gender, age, BMI, degree of airflow obstruction (i.e., FEV 1 ), comorbidity and chronic treatment. Multiple computed tomography (CT) scan slices were obtained to assess area and attenuation coefficients of multiple upper limb, thorax, abdomen and lower limb muscles. p Z 0.027). CSA and attenuation coefficients of all other muscle compartments showed no statistical differences between the two study groups but showed the same trend. Strength of the inspiratory and expiratory muscles did not differ between the two study groups.
Summary
Background: The potential role of decreased respiratory muscle mass, if any, in mediating the susceptibility to exacerbation in COPD patients has not been determined. We hypothesized that a decrease in respiratory muscle mass is associated with increased risk of multiple hospital admissions due to acute exacerbations of the disease. Methods: Eligible cases and controls (n Z 20) were identified from records of our department's pulmonary clinic. Ten subjects diagnosed with COPD (males, 66 AE 7 yr, Body Mass Index (BMI) Z 26 AE 4 kg/m 2 ) were identified as fragile patients. Fragility was defined as four or more admissions in the previous year due to severe exacerbations of the disease. Fragile patients were matched with 10 non-fragile controls, defined as COPD patients who had required only one admission due to exacerbation of the disease. Criteria for 1:1 matching included ethnicity, gender, age, BMI, degree of airflow obstruction (i.e., FEV 1 ), comorbidity and chronic treatment. Multiple computed tomography (CT) scan slices were obtained to assess area and attenuation coefficients of multiple upper limb, thorax, abdomen and lower limb muscles.
Results: CSA of intercostal and abdominal muscles was significantly decreased in fragile COPD patients (right side intercostals, mean relative difference (MRD) Z À14%, p Z 0.010; OR (95% CI) Z 2.2 (1.1e4.8), p Z 0.021; left side, MRD Z À13%, p Z 0.007; OR Z 2.2 (1.1e4.5),
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex blend of signs and symptoms in patients with chronic bronchitis and emphysema. 1 COPD is a major public health problem throughout the world because it is a major cause of morbidity and premature mortality. It jeopardizes the quality of life of patients and imposes enormous global healthcare costs. 1e3 In Spain, COPD affects about 9% of the adult population (40e70 years old) and is the fourth cause of hospital admission and death in this age group. 4 COPD has a variable natural history. Some COPD patients showed a greater risk for frequent and severe exacerbations. An exacerbation of COPD is defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum that is beyond normal day-to-day variations, is acute in onset and may warrant a change in regular medication in a patient with underlying COPD. 1 Exacerbations of COPD have a high rate of mortality, which worsens with advancing age. 5 Mortality increases with the frequency of severe exacerbations, particularly if these require admission to hospital. 6 In our setting, it has been shown that the patients with the greatest mortality risk are those with three or more acute COPD exacerbations (hazard ratio 4.13). 6 Skeletal muscle function (strength and endurance) is closely related to the absolute quantity of muscle mass, which is reduced with aging. 7e10 This decrease in muscle mass (sarcopenia) is thought to contribute to the development of functional limitations and disability in old age and to be a potential explanation for part of the association between muscle strength and mortality. 11, 12 Respiratory muscles are essential to alveolar ventilation. The potential role of decreased respiratory muscle mass, if any, in mediating the susceptibility to severe exacerbation in COPD patients has not been determined. In patients with COPD, these muscles work against increased mechanical loads due to airflow limitation, geometrical changes in the thorax and decreased compliance of the chest contents. 13 During an exacerbation there is increased hyperinflation and air trapping, with reduced expiratory flow and worsening of V A /Q abnormalities, resulting in severe hypoxemia and increased mechanical load and dyspnea. 1, 14, 15 We hypothesized that a decrease in respiratory muscle mass is associated with an unstable balance between functional muscle reserve and chronic mechanical and metabolic loadings in COPD patients prone to acute exacerbations of the disease, and that this change may be unnoticed by measurements of muscle strength only. In this study, we sought to determine whether low respiratory muscle mass, measured with computed tomography (CT) scanning, would reflect an increased risk for exacerbation in COPD patients after adjusting for risk indicators, including age, degree of airflow obstruction, comorbidities and nutritional status. Finally, we were able to compare associations on the basis of isometric inspiratory and expiratory muscle strength.
Condensed methods Ethics and study design
The cross-sectional study was designed according to the guidelines for human research 16 and approved by the Research Committee of Human Investigation at the Municipal Institute for Medical Research (IMIM). The purposes and characteristics of the study were fully explained to the patient, without revealing any a priori hypothesis, and written informed consent was obtained from each participant.
Sample size
The sample size estimate indicates that 10 patients in the fragile group compared with 10 non-fragile patients would permit the detection of 30% of decrease in the crosssectional area (CSA) of skeletal muscles, considering a risk of a < 0.05 and b < 0.20, in bilateral contrast, and estimating a loss of 30%. Calculation of this sample size was based on the results of a previous study conducted and published by our group. 17 
Diagnosis of COPD
Cases and controls were diagnosed with COPD by assessment of both the signs and symptoms of chronic bronchitis and/or pulmonary emphysema, along with functional criteria of chronic and irreversible airflow obstruction (FEV 1 /FVC < 70%, FEV 1 < 80% pred) and absence of asthma as assessed by clinical history and response to bronchodilators (change <12% in FEV 1 following 400 mg of inhaled salbutamol).
18e21 Current and former smokers were included. We followed the guidelines for grading disease severity in COPD contained in the ATS/ERS guidelines for staging of COPD. 18 
Identification of ''fragile'' COPD patients
For a patient to be enrolled as a case, both a diagnosis of COPD and absence of comorbidity were required. Fragility was defined on the basis of the number of admissions (four or more) in the previous year due to exacerbations of the disease. Severe exacerbations were predefined as hospital admissions due to acute worsening in PaCO 2 associated with change in the patient's baseline dyspnea, cough and/or sputum that was beyond normal day-to-day variations. Eligible cases were identified from records of the pulmonary outpatient clinic and pulmonary function test laboratory of our department. The population of cases consisted of men older than 50 years, born and living in Spain, who required multiple admissions in the Department of Respiratory Medicine of the Hospital del Mar (Barcelona, Spain) due to acute exacerbation of COPD during 2006e2007. At the time of evaluation, patients with COPD were stable with no exacerbation of their disease in the preceding two months and had not experienced recent weight loss. Patients with COPD receiving regular treatment with systemic corticosteroids or under long-term oxygen therapy were excluded. Patients submitted to invasive mechanical ventilation or intensive care management were not eligible for the study.
Identification of ''non-fragile'' COPD controls
For a subject to be enrolled as a control, a diagnosis of COPD and absence of comorbidity were required. The population of controls consisted of men older than 50 years showing COPD who required their very first admission due to exacerbation of the disease or any other cause. Although respiratory muscle thickness does not change significantly with age, 22 age does associate with changes in both 
4 (40) 3 ( isometric and dynamic strength 23 and is a known risk factor for COPD. 1 On the basis of a 1:1 multivariable matching, we included ethnicity, gender, age, body mass index (BMI), degree of airflow obstruction (i.e., FEV 1 ), comorbidity (i.e., Charlson index) and chronic treatment as criteria to establish the closest possible case:control match within each continuous variable interval. Age intervals were 50e59, 60e69 and 70e79 years. BMI intervals were 20e29.9 and 30e40 kg/m 2 . FEV 1 intervals were according to present ATS/ERS guidelines for staging of COPD. 18 The Charlson index was included as a method to classify comorbidity. 24 
Smoking status data
This was collected via a questionnaire. Exhaled CO was included as a measure to confirm nicotine withdrawal or continued smoking. Subjects were classified as former smokers or current smokers.
Nutritional and functional evaluations
Nutritional assessment, pulmonary function tests, and inspiratory (PI max ) and expiratory (PE max ) muscle strength during maximal maneuvers were measured in each patient and compared with reference values, as described elsewhere 25 and in the Supplementary data.
CT and muscle morphometry
CT was performed at different anatomic levels using a fourrow detector (Somatom Sensation 4, Siemens, Ehrlangen, Germany) to estimate muscle mass and density of multiple muscle compartments. 26 Computer assisted image software was used for the analyses. Technical and methodological specifications appear in the Supplementary data.
Statistical analysis
Subject characteristics are expressed as mean (standard deviation [SD]) or percentage. Mean values of muscle CT imaging variables were compared using ManneWhitney U test. A conditioned multivariate logistic regression model was used to obtain the association between fragility and CSA of muscle groups after adjusting for potential confounders. 27 We tested for interactions between tobacco smoke and fragility with the logistic model. A p value of less than 0.05 was considered statistically significant. All reported p values are two-sided. The analysis was performed by two investigators (MOL and JGA), using SPSS for Windows Release 15.0 (2006, SPSS Inc., Chicago, IL, USA). Table 1 shows the main clinical and functional characteristics of the 20 subjects (mean age, 66 yr) included in the present study. All were male smokers with COPD. Demographic and anthropometric characteristics of the fragile patients who required multiple hospitalizations were comparable to the control group. Smoking exposure and pulmonary function variables were similar between the two study groups. Strength of the inspiratory and expiratory muscles did not differ between the two study groups. Moreover, PI max and PE max showed no linear function with the degree of airflow obstruction, air trapping, or total lung capacity (Fig. 1 Fig. 1a, b and c, respectively) . A linear function is lacking between pulmonary function and maximal inspiratory (PI max , :) or expiratory (PE max , C) pressures measured at the mouth in this study population. Confidence intervals (95%) are depicted as dotted lines (for PI max ) and continuous lines (for PE max ). Respiratory muscle endurance was not assessed.
Results

Patient characteristics
CT area and density of multiple muscle compartments
Using a four-row detector CT (Somatom Sensation 4, Siemens, Ehrlangen, Germany) a CT at normalized anatomic levels ( Fig. 2 ) was performed to estimate muscle mass and density of multiple muscle compartments (Figs. 3 and 4) . Table 3 summarize the mean values of both the size and attenuation coefficients obtained by measuring upper limb, lower limb, chest and abdomen muscle compartments in the two study groups. Costal diaphragm and neck muscles were not included in the present study assessments. To perform interindividual comparisons, we calculated individual ratios between each muscle area and the femur area ( Table 2 ). The product of muscle CSA times attenuation coefficient (i.e., Hounsfield units) was included as an index of muscle mass. We were able to compare associations on the basis of isometric inspiratory and expiratory muscle strength. Statistically significant differences were observed at intercostal compartments even when adjusted for potential confounders (age, BMI and FEV 1 ) (Fig. 5) . Structural impairment of the respiratory muscles was greater than in other muscle compartments. Fig. 4 demonstrates that such a difference is evident even at first glance on CT images. CSA of intercostal muscles was significantly decreased in fragile COPD patients (for right side: mean relative difference (MRD) Z À14%, p Z 0.010; OR (95% CI) Z 2.2 (1.1e4.8), p Z 0.021; for left side: MRD Z À13%, p Z 0.007; OR Z 2.2 (1.1e4.5), p Z 0.027; Table 2 , and Fig. 5 ). Attenuation coefficients of intercostals were decreased in fragile COPD (for right side, MRD Z À10%, p Z 0.001; for left side, MRD Z À9%, p Z 0.004; Table 2) . Individual values of all study patients are depicted in Fig. 7 to show that size (CSA) of intercostal muscles is comparable and linearly correlated (r 2 Z 0.938, p < 0.001) between right and left body compartments. We attempted to estimate linear correlation between respiratory muscle strength vs. intercostals and abdominal muscle mass; however, statistical significance was not reached (Figs. 5  and 6 ). Difference in abdominal muscles was close to statistical significance (MRD Z À27%, p Z 0.052; Table 2 ). The association between intercostal CSA and fragility of COPD remained statistically significant after adjustments by age, BMI and smoking. CSA and attenuation coefficients of all other muscle compartments showed no differences between the two study groups. Despite the lack of Figure 2 Topographic definition of anatomical levels of acquisition of muscle CT images. To standardize levels of image acquisition, we defined the levels of acquisition from a long topogram (1.024 mm), ranging from the lower portion of the neck to below the knees (Fig. 2) , with the patient in the supine position, having legs and feet together and arms next to the body, palms resting on the side walls of the thighs. From this topogram we defined three levels of image acquisition: 1) axial images of the nondominant arm, obtained at the midpoint between the proximal and distal ends of the humerus, 2) leg images, at the midpoint of the segment between cranial and caudal ends of the femur, and 3) abdomen images, at the level of iliac crest. statistical significance, changes in the other muscle compartments showed the same trend (Tables 2 and 3) .
Discussion
The present study demonstrates that patients susceptible to multiple exacerbations (i.e., fragile COPD) show a decrease in intercostal muscle mass. Both the attenuation coefficients and area of all other muscle compartments (upper limb, paravertebrals, psoas and lower limb muscles) were comparable to patients without prior hospital admissions (i.e., non-fragile COPD). These results reinforce other findings that COPD associates with not only pulmonary but also extra-pulmonary alterations 28 and that selected muscle compartments disclose earlier and/or greater impairment than others. Furthermore, the results allow the authors to suggest that specific respiratory muscle wasting is a predictive variable of susceptibility to and/or the consequence of severe exacerbations and the likelihood of hospitalization for COPD patients.
A low BMI has been shown to be an independent indicator of poor prognosis in patients with COPD. 29e32 A new severity classification was proposed: the BODE index (BMI, airflow obstruction, dyspnea and exercise capacity). 33 Nevertheless, it is generally suggested that the true factor underlying the negative effects attributed to malnutrition is muscle depletion, not total body weight loss. 34, 35 The assessment of nutritional status based on summary measures such as body weight or BMI has limitations, since it affords no qualitative information on body composition. Using CT, Heymsfield and Williams 36 showed a 20e25% overestimation in arm muscle area. In an effort to overcome the limitation of these summary measures, we selected a multi-slice CT anthropometric assessment for the present study. X-ray or other anthropometric techniques can detect particular changes in some muscle compartments even when BMI and body weight are preserved. 26 Bernard et al. 37 demonstrated that the strength of the thigh linearly correlates with muscle CSA evaluated by CT in COPD patients. Marquis et al. 38 showed that a decrease in the CSA of the thigh ( 70 cm 2 ) associated with fourfold increase of mortality risk, independently of other prognostic variables. Finally, Soler-Cataluna et al. 39 demonstrated that depletion of middle arm muscle area is an even better predictor of mortality than BMI in normal weight or overweight patients with COPD.
Our study offers additional evidence supporting the concept that focal muscle atrophy or wasting associates with multiple exacerbations. These findings demonstrate that focal decrease of the mass of selective respiratory muscle compartments characterizes the group of COPD patients with greater risk of severe exacerbations. Statistically significant differences were observed despite the limited sample size involved. We found that the development of respiratory muscle wasting is prior and greater to that in Figure 5 Cross-sectional area of intercostal muscles is decreased in fragile COPD as compared with non-fragile COPD patients. Individual and mean measures of all study patients are depicted in the figure. Significant differences were evident in the intercostal muscle area between fragile (-) and non-fragile (,) COPD patients. Despite this structural difference in the intercostal muscle compartment, maximal mouth pressures (PI max and PE max ) were not different between the two study groups. Figure 6 Cross-sectional area of abdominal muscles in fragile COPD as compared with non-fragile COPD patients. Abdominal muscles showed a tendency to be depleted in fragile (-) as compared with non-fragile (,) COPD patients but statistical significance was not achieved.
other trunk or limb muscle compartments. However, the design of the study does not permit total confidence that the structural changes within the external intercostals are representative of inspiratory muscles in general. We attempted to estimate the correlations between intercostal and abdominal muscle mass and respiratory muscle strength; however, the correlation was not satisfactory, probably due to the participation of other accessory respiratory muscles in the maneuvers. This lack of difference in muscle strength suggests that other variables (e.g., muscle endurance) should be considered as a critical outcome in the study of clinically stable COPD patients. We support this interpretation of previous data from a study assessing the lack of linear relationships between strength and endurance of other muscles in COPD patients. 40 Nevertheless, we speculate that the absence of differences or correlations between CSA and muscle strength could also reflect the possibility of interactions between variables and several possibilities incorporating confounders. In this sense, it is not possible to identify the specific contribution of intercostals in these maneuvers: the mass or length of the diaphragm was not assessed; a potential lengthetension adaptation of the diaphragm (justified by the sum of individual sarcomere shortening) could coexist 41 ; CT images did not permit differentiation between internal (expiratory) and external (inspiratory) intercostal muscle areas; strength maneuvers (PI max and PE max ) were performed against an occludable mouthpiece during isovolume (isometric) contraction of the muscles, but isokinetic differences cannot be discarded; it is possible that the magnitude of the lengtheningeshortening CSA can affect the differences between the two COPD groups; a structural change from I / II in the myosin heavy chain isotype could partially preserve strength at the expense of endurance; and finally, compliance of the system (lung, chest, abdomen) and lung volumes are not included in the estimation of normal predicted values of respiratory muscle strength. Similarly, Vitacca et al. 42 were unable to identify respiratory muscle function in last stable state as a predictor of functional worsening (predefined as worsening in PaCO 2 , PI max and FEV 1 ) following a period of hospitalization in an intensive care unit due to exacerbation of COPD. It is remarkable that blood gases and dynamic and static lung volumes also showed a lack of predictive capacity in that study. 42 Circumstantial evidence supports the relevance of our study findings. Most variables identified as risk factors for exacerbation and hospital readmission in COPD patients can impair respiratory muscle structure and function, directly or indirectly.
43e46 A multi-center study by Garcia-Aymerich et al. 15 in our own study setting found that risk of repeated exacerbations associates with multiple preventable factors such as sedentarism, smoking history, lack of prescription for (or no adherence to) home oxygen therapy, and lack of respiratory rehabilitation. As shown in Table 1 , distribution of all these variables was comparable between the two study groups. These patient selection criteria imply that other risk factors, in addition to gender, age, degree of airflow obstruction, comorbidity, chronic respiratory failure, chronic corticosteroid treatment or comorbid conditions, must be considered a critical cause(s) of selected intercostal muscle wasting in fragile COPD patients.
Potential clinical implications
Respiratory muscle dysfunction in patients with COPD is not merely a descriptive or anecdotal description. It is associated with relevant characteristics such as an increase in certain symptoms (e.g., dyspnea) and signs (hypercapnia, decrease in exercise capacity). 47 Although the descriptive design of the study does not allow us to establish a causeeeffect relationship and the pathophysiology of exacerbations in chronic respiratory diseases appears to be multifactorial, the present study's selection criteria diminish interaction and biases and make it possible to hypothesize possible physiopathological associations. Interestingly, the present report found that intercostal mass is an additional predictive variable of susceptibility to and/or the consequence of severe exacerbations in patients with COPD. It seems probable that different pathogenic mechanisms related to muscle wasting, and potentially present during exacerbations (e.g., inflammation, oxidative stress, hypoxemia, acidosis), may explain the present findings. 48 We cannot discard, however, an intrinsic susceptibility to respiratory muscle injury and wasting in the face of chronic mechanical load imposed by the disease. 25 Identification of these structural changes in susceptible COPD patients could have important implications for specific strategies such as respiratory muscle training or anabolic treatments. Altogether, these arguments suggest that CSA of the intercostal compartment can be proposed as an additional (non-redundant) variable offering information in addition to that obtained only with measurements of maximal mouth pressures, a fact that is biologically plausible and offers potential clinical implications. Intercostal wasting might have occurred prior to, secondary to or in correlation with exacerbations, and may develop during, afterwards, or both. Irrespective of the details of this causeeeffect relationship, intercostal atrophy is statistically associated with exacerbation rate (risk), a fact that has significant relevance in the clinical scenario of COPD.
We would not propose CT scan as a screening technique nor periodical imaging study for the assessment of respiratory muscle mass (i.e., CSA) in all patients with COPD. It is probable, however, that muscle imaging (CT or others) could be proposed as complementary assessments in all fragile patients. Intercostal mass appears as an additional predictive variable of susceptibility to and/or the consequence of severe exacerbations in patients with COPD. The potential role of other imaging techniques such as ultrasonography, which discloses no ionizing radiation risk, should be evaluated before recommending CT scan as the ideal muscle imaging technique. Identification of these structural changes in susceptible COPD patients could have important implications for specific strategies such as respiratory muscle training or anabolic treatments in a group of patients with typical fragility and clinical characteristics.
Conclusions
In this report, we show that the risk for multiple admissions due to exacerbation of COPD associates with a marked decrease in the CSA of the intercostal muscle compartment, even in the absence of nutritional depletion and comparable morphology of peripheral muscle compartments. This impairment in intercostal and abdominal muscles is underestimated when assessing maximal pressures at the mouth. Further studies could identify this compartmentalized muscle atrophy in fragile COPD patients as a target for specific strategies such as respiratory muscle training or anabolic treatments.
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